Specialists acknowledge the need for implementing a comprehensive care model, supported in medical device

  • The Mexican office of Becton Dickinson, through their BD Ultra Fine diabetes specialized department, sums efforts with the Mexican Association of Nurses in Nephrology, A.C. (AMENAC, by its acronym in Spanish), PiSA® Biotec, affiliated company of Grupo PiSA® and the platform Doctoranytime.
  • World Diabetes Day is considered the most important international campaign to raise awareness and sensitize about the situation of diabetes in the world.
  • The World Health Organization (WHO), chose the motto “Nursing staff makes the difference” as the central axis for this year’s campaign, to raise awareness about the fundamental role of this health professionals.

A comprehensive model of care based on prevention, timely diagnosis, care and control of the disease, as well as adherence to treatment, can be achieved thanks to the technological development of medical devices that the health industry has created with the purpose of improving the patients’ quality of life.

According to the 2018 National Health and Nutrition Survey (ENSANUT, for its acronym in Spanish), around 8.6 million Mexicans live with diabetes, of which 50% do not take actions to control this disease or delay its complications, which include: decreased vision or total loss of sight, limb amputations due to the presence of ulcers, as well as Chronic Kidney Disease (CKD).

Within the framework of World Diabetes Day, during a virtual press conference, Irma Luisa Ceja Martínez, Medical Manager of Endocrinology and Nutrition at Grupo PiSA®, explained that technological innovation has allowed people living with diabetes to have access to medical devices, applications and platforms that facilitate the proper control of your blood sugar levels, as well as the application of insulin.

“Currently, people living with diabetes have several treatment options available to care for and control this disease, as well as the use of administration devices for different types of insulin that facilitate adherence to treatment to achieve better quality of life. The devices are accessible in the market and help reduce expenses and complications associated with this illness” explained Ceja Martínez, also governor of the Mexican Chapter of the American College of Physicians (ACP).

The internal medicine specialist recalled that PiSA® Farmacéutica, a 100% Mexican company with 75 years of history, has dedicated almost three decades to the development of a broad portfolio of diabetes medications, such as Insulin Glargine, the first Biocomparable Biotechnological Drug (MBB) in obtaining sanitary registration in Mexico (2015). Becton Dickinson (BD) and Grupo PiSA®, through PiSA® Biotec, brought together talents to develop a cartridge device with this type of insulin, a comprehensive solution accessible to people living with diabetes and that facilitates greater control of this disease.

 

Becton Dickinson (BD) is an international medical technology company dedicated to advancing the world of healthcare by improving medical discovery, diagnosis, and patient care. It promotes good clinical laboratory and research practices to support the treatment of diabetes.

In this regard, Ana Laura Segundo, BD Ultra Fine Diabetes Education Coordinator, commented: “At Becton Dickinson we work permanently to offer innovative injection drug administration systems that improve the experience for the patient, contribute to adherence to treatment, help reduce costs associated with the disease, and have a positive impact on its comprehensive management. The company not only seeks to generate strategic alliances to promote the development of new devices and the use of digital platforms, it also encourages the promotion and prevention of health to achieve models of care for diabetes”.

On the occasion of World Diabetes Day and its central theme: “Nursing staff make a difference”, Fernando Orozco Quiroz, president of the Mexican Association of Nurses in Nephrology, A.C. (AMENAC, for its acronym in Spanish), highlighted the fundamental role played by nurses from diagnosis to treatment of diabetes in our country, and recalled the close relationship that exists between damage to kidney function and poorly controlled diabetes.

“Nursing staff are often the first contact that a person living with diabetes interacts with after a medical diagnosis. They are also in charge of training patients in both preventive measures and treatment, so it is important that this sector be permanently trained, which during this COVID-19 pandemic, has made great efforts. For them, our recognition and gratitude”, emphasized Orozco Quiroz, who has a Nursing degree.

Finally, María Emilia Salazar, Country Manager of Doctoranytime, emphasezed the importance of a person with diabetes not interrupting their medical treatment, since a lack of control can cause both acute and chronic complications. In this sense, digital platforms and tools have helped many patients to have remote care, reducing the risks involved in leaving home for this vulnerable sector, particularly during this pandemic.

“We launched the telemedicine tool as a solution for doctors to keep their consultations active during the COVID-19 pandemic. Over time, we realized that it is an excellent complement and ally for patients with chronic diseases such as diabetes, since it allows them to have greater adherence to their treatments and better control of their condition. To date, 43% of our specialists use it. Furthermore, according to the American Medical Association, 74% of face-to-face consultations could be replaced by telemedicine, and a good percentage of these are related to patients with chronic diseases,” pointed the Mexican based directive.

Comparte esta publicación

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email